These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22153931)

  • 41. Targeting dendritic cells--why bother?
    Kreutz M; Tacken PJ; Figdor CG
    Blood; 2013 Apr; 121(15):2836-44. PubMed ID: 23390195
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement.
    Caminschi I; Proietto AI; Ahmet F; Kitsoulis S; Shin Teh J; Lo JC; Rizzitelli A; Wu L; Vremec D; van Dommelen SL; Campbell IK; Maraskovsky E; Braley H; Davey GM; Mottram P; van de Velde N; Jensen K; Lew AM; Wright MD; Heath WR; Shortman K; Lahoud MH
    Blood; 2008 Oct; 112(8):3264-73. PubMed ID: 18669894
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting Conventional Dendritic Cells to Fine-Tune Antibody Responses.
    Tesfaye DY; Gudjonsson A; Bogen B; Fossum E
    Front Immunol; 2019; 10():1529. PubMed ID: 31333661
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhancing vaccine antibody responses by targeting Clec9A on dendritic cells.
    Park HY; Tan PS; Kavishna R; Ker A; Lu J; Chan CEZ; Hanson BJ; MacAry PA; Caminschi I; Shortman K; Alonso S; Lahoud MH
    NPJ Vaccines; 2017; 2():31. PubMed ID: 29263886
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting human dendritic cells in situ to improve vaccines.
    Sehgal K; Dhodapkar KM; Dhodapkar MV
    Immunol Lett; 2014 Nov; 162(1 Pt A):59-67. PubMed ID: 25072116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of protective immunity against microbial challenge by targeting antigens expressed by probiotic bacteria to mucosal dendritic cells.
    Mohamadzadeh M
    Curr HIV Res; 2010 Jun; 8(4):323-9. PubMed ID: 20353394
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Controlling the speed of antigens transport in dendritic cells improves humoral and cellular immunity for vaccine.
    Song Z; Jiao L; Wang D; Qiu Y; Miao J; Zhu T; Yu R; Wang Z; Zhou Y; Cai T; Zhang S; Liu H; Sun H; Sun Y; Liu Z
    Biomed Pharmacother; 2024 Aug; 177():117036. PubMed ID: 38941888
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD301b
    Kumamoto Y; Hirai T; Wong PW; Kaplan DH; Iwasaki A
    Elife; 2016 Sep; 5():. PubMed ID: 27657168
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting dendritic cells: a promising strategy to improve vaccine effectiveness.
    Macri C; Dumont C; Johnston AP; Mintern JD
    Clin Transl Immunology; 2016 Mar; 5(3):e66. PubMed ID: 27217957
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent advances and new opportunities for targeting human dendritic cells in situ.
    Dhodapkar MV; Dhodapkar KM
    Oncoimmunology; 2014; 3(8):e954832. PubMed ID: 25610750
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics.
    Wallace RP; Refvik KC; Antane JT; Brünggel K; Tremain AC; Raczy MR; Alpar AT; Nguyen M; Solanki A; Slezak AJ; Watkins EA; Lauterbach AL; Cao S; Wilson DS; Hubbell JA
    Cell Rep Med; 2024 Jan; 5(1):101345. PubMed ID: 38128533
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Engineering adjuvants for predictable immunity.
    Reed SG
    J Exp Med; 2014 Jun; 211(6):1008-9. PubMed ID: 24890115
    [No Abstract]   [Full Text] [Related]  

  • 53. Studies on the rôle of lymphocytes in antibody production.
    WESSLEN T
    Acta Derm Venereol; 1952; 32(4):265-73. PubMed ID: 14932675
    [No Abstract]   [Full Text] [Related]  

  • 54. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments.
    Zhang JG; Czabotar PE; Policheni AN; Caminschi I; Wan SS; Kitsoulis S; Tullett KM; Robin AY; Brammananth R; van Delft MF; Lu J; O'Reilly LA; Josefsson EC; Kile BT; Chin WJ; Mintern JD; Olshina MA; Wong W; Baum J; Wright MD; Huang DC; Mohandas N; Coppel RL; Colman PM; Nicola NA; Shortman K; Lahoud MH
    Immunity; 2012 Apr; 36(4):646-57. PubMed ID: 22483802
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evolution of B cell responses to Clec9A-targeted antigen.
    Park HY; Light A; Lahoud MH; Caminschi I; Tarlinton DM; Shortman K
    J Immunol; 2013 Nov; 191(10):4919-25. PubMed ID: 24123689
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas.
    Picco G; Beatson R; Taylor-Papadimitriou J; Burchell JM
    Eur J Immunol; 2014 Jul; 44(7):1947-55. PubMed ID: 24648154
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune imprinting and next-generation coronavirus vaccines.
    Huang CQ; Vishwanath S; Carnell GW; Chan ACY; Heeney JL
    Nat Microbiol; 2023 Nov; 8(11):1971-1985. PubMed ID: 37932355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccine adjuvants: mechanisms and platforms.
    Zhao T; Cai Y; Jiang Y; He X; Wei Y; Yu Y; Tian X
    Signal Transduct Target Ther; 2023 Jul; 8(1):283. PubMed ID: 37468460
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficient antigen delivery by dendritic cell-targeting peptide via nucleolin confers superior vaccine effects in mice.
    Matsuda T; Misato K; Tamiya S; Akeda Y; Nakase I; Kuroda E; Takahama S; Nonaka M; Yamamoto T; Fukuda MN; Yoshioka Y
    iScience; 2022 Nov; 25(11):105324. PubMed ID: 36304121
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Splenic Dendritic Cells and Macrophages Drive B Cells to Adopt a Plasmablast Cell Fate.
    McNamara HA; Lahoud MH; Cai Y; Durrant-Whyte J; O'Connor JH; Caminschi I; Cockburn IA
    Front Immunol; 2022; 13():825207. PubMed ID: 35493521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.